drugset

drugset / Trial / NCT06973564

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

NCT06973564 ↗

Phase 1/2 Recruiting 294 enrolled Jacobio Pharmaceuticals Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

Timeline

Start: 2025-05-29
Primary completion: 2027-11
Completion: 2028-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JAB-23E73	Unknown	—	Oral

Indications